UY33499A - Formulaciones que comprenden particulas finas recubiertas - Google Patents

Formulaciones que comprenden particulas finas recubiertas

Info

Publication number
UY33499A
UY33499A UY0001033499A UY33499A UY33499A UY 33499 A UY33499 A UY 33499A UY 0001033499 A UY0001033499 A UY 0001033499A UY 33499 A UY33499 A UY 33499A UY 33499 A UY33499 A UY 33499A
Authority
UY
Uruguay
Prior art keywords
oral cavity
formulations
include fine
covered particles
fine covered
Prior art date
Application number
UY0001033499A
Other languages
English (en)
Inventor
Nakamura Kazuhiro
Ogawa Teppei
Akutagawa Tomoya
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of UY33499A publication Critical patent/UY33499A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

La presente invención se refiere a una tableta que se desintegra rápidamente en la cavidad bucal, que comprende como principio activo ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico, que es una formación que virtualmente no causa ninguna sensación de irritación en la cavidad bucal o la faringe y conserva buenas propiedades de disolución y desintegración en la cavidad bucal aun cuando se almacene en condiciones de alta temperatura y alta humedad.
UY0001033499A 2010-07-09 2011-07-08 Formulaciones que comprenden particulas finas recubiertas UY33499A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010156874 2010-07-09

Publications (1)

Publication Number Publication Date
UY33499A true UY33499A (es) 2012-01-31

Family

ID=45441336

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033499A UY33499A (es) 2010-07-09 2011-07-08 Formulaciones que comprenden particulas finas recubiertas

Country Status (23)

Country Link
US (1) US20130101670A1 (es)
EP (1) EP2591781B1 (es)
JP (1) JP5000017B2 (es)
KR (1) KR20130113348A (es)
CN (1) CN102958522B (es)
AR (1) AR082139A1 (es)
AU (1) AU2011274851A1 (es)
BR (1) BR112013000298A2 (es)
CA (1) CA2804874C (es)
CL (1) CL2013000089A1 (es)
CO (1) CO6650363A2 (es)
EC (1) ECSP12012360A (es)
ES (1) ES2644064T3 (es)
MA (1) MA34460B1 (es)
MX (1) MX2013000282A (es)
NZ (1) NZ605562A (es)
PE (1) PE20131064A1 (es)
RU (1) RU2013105456A (es)
TN (1) TN2012000623A1 (es)
TW (1) TW201217001A (es)
UY (1) UY33499A (es)
WO (1) WO2012005365A1 (es)
ZA (1) ZA201300106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130574A1 (es) 2010-06-16 2013-06-01 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EP2613780B1 (en) 2010-09-10 2014-11-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
JP4300652B2 (ja) 1998-09-21 2009-07-22 大正製薬株式会社 経口用固形製剤
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
CN101982199A (zh) * 2001-11-21 2011-03-02 卫材R&D管理有限公司 含有对酸不稳定的生理活性化合物的制剂组合物及其制法
JP2005023058A (ja) 2003-06-10 2005-01-27 Lion Corp 咀嚼型医薬製剤用薬物粒子及びその製造方法、並びに薬物粒子を含有する咀嚼型医薬固形製剤及びその製造方法
JP5062872B2 (ja) 2003-08-13 2012-10-31 東和薬品株式会社 不快な味を低減した口腔内崩壊錠剤
CA2619745A1 (en) * 2005-08-18 2007-02-22 Teijin Pharma Limited Tablet with multiple drug-containing sections
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5097488B2 (ja) 2006-09-13 2012-12-12 京都薬品工業株式会社 苦味マスキング
PE20130574A1 (es) * 2010-06-16 2013-06-01 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Also Published As

Publication number Publication date
TN2012000623A1 (en) 2014-04-01
EP2591781A4 (en) 2014-12-03
RU2013105456A (ru) 2014-08-20
WO2012005365A1 (ja) 2012-01-12
CO6650363A2 (es) 2013-04-15
TW201217001A (en) 2012-05-01
BR112013000298A2 (pt) 2016-05-31
MX2013000282A (es) 2013-02-11
US20130101670A1 (en) 2013-04-25
ES2644064T3 (es) 2017-11-27
EP2591781B1 (en) 2017-09-27
CN102958522B (zh) 2015-12-16
JPWO2012005365A1 (ja) 2013-09-05
MA34460B1 (fr) 2013-08-01
AU2011274851A1 (en) 2013-01-31
KR20130113348A (ko) 2013-10-15
ZA201300106B (en) 2013-09-25
PE20131064A1 (es) 2013-09-23
CA2804874C (en) 2019-07-23
CN102958522A (zh) 2013-03-06
NZ605562A (en) 2013-11-29
ECSP12012360A (es) 2013-02-28
CL2013000089A1 (es) 2013-03-08
AR082139A1 (es) 2012-11-14
JP5000017B2 (ja) 2012-08-15
EP2591781A1 (en) 2013-05-15
CA2804874A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2014186742A3 (en) Anhydrous hydrogel composition
UY33499A (es) Formulaciones que comprenden particulas finas recubiertas
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
TN2015000326A1 (en) Tamper resistant pharmaceutical formulations
WO2010033832A3 (en) Estriol formulations
BR112013006597A2 (pt) tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo
CL2011002755A1 (es) Composicion farmaceutica topica que comprende particulas de fosfato de calcio nanoporosas, esfericas, donde al menos 90% o mas de las particulas tienen un diametro promedio de 2 micrometros o menos y estan enlazadas a un agente farmacologicamente activo.
NZ619857A (en) A fast dissolving pharmaceutical composition
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
EP2328550A4 (en) MUCOADHERENT COMPOSITIONS AND THEIR USE
PE20140255A1 (es) Tableta dispersable en forma oral
BR112014027582A2 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
MY174729A (en) Pharmaceutical combination drug
BR112012027794A2 (pt) tablete entérico
BR112015030431A2 (pt) formulação de liberação modificada
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
BR112013000300A2 (pt) comprimido que se desintegra intraoralmente
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
PH12015502274B1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
ECSP11010998A (es) Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.
BRPI0907203A2 (pt) Forma galênica para a administração de triptanos via transmucosa oral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807